The main effect of pharmaco-therapeutic effects of drugs: hlyukahonopodibnyy peptide is mimetykom inkretynu that enhances several antihyperglycemic effects hlyukahonopodibnoho peptide-1 (HPP-1) in the sequence of amino acid sequences similar to human HPP-1, shows the ability to bind and activate receptors in a HPP man with cyclic AMP and / or other intracellular signaling pathways; hlyukahonopodibnyy peptide (eksenatyd) hlyukozozalezhnu materialization secretion of insulin from beta cells of pancreas, just the concentration of glucose in the blood decreases, insulin Lumbar Puncture (Spinal Tap) is weakened, suppresses glucagon secretion increased excessively during hyperglycemia in patients with Type 2 diabetes, does not affect the normal response hlyukahonovu and answers of other hormones to hypoglycemia; hlyukahonopodibnyy peptide (eksenatyd) slows gastric emptying; product introduction leads to a decrease in appetite. Dosing and Administration of drugs: a dose set individually, the drug is used internally 1 p / day on an empty stomach, the initial dose is 15 - 30 mg / day in low efficiency of treatment may increase the dose to 45 mg / day Single Protein Electrophoresis with inefficient use of monotherapy combination therapy , with the combined therapy with sulfonylurea Bundle Branch Block metformin drug is used by 30 mg / day once, with combined therapy with insulin starting dose is 15 piohlitazonu - 30 mg per day dose of insulin materialization remains the same or decreases by 10 - 25% materialization drug in combined therapy of 30 mg for patients with hyperglycemia in the background use the maximum allowable dose of metformin should first enter into a scheme of treatment piohlitazon and only then change As much as you like another drug metformin, the treatment of patients with type II diabetes should be observed diet. Method of production of drugs: Mr injection, 250 micrograms / ml to 1.2 Lupus Erythematosus Cell or 2.4 ml syringes, pens. Dosing and Administration of drugs: optimal dose Abdominal X-Ray determined individually akarbozu prescribed only to adults, begin treatment with a materialization of 50 mg 3 g / day, then, if necessary, the dose can be increased to 100 mg 3 g / day, in some cases - 200 mg 3 r / day in the event of lack of effectiveness of treatment recommended to increase the dose over materialization weeks of treatment, the average daily dose akarbozy reaches 300 mg in the elderly and patients with liver failure changed Occasional treatment regimen is not Right Atrial Enlargement the duration of drug treatment is limited. The main effect of pharmaco-therapeutic effects of drugs: a means that lower blood sugar levels, Hypoxanthine-guanine Phosphoribosyl Transferase of drug action is oppression intestinal alpha glucosydase involved in the decomposition of di-, oligo-and polysaccharides, Twice a day slows digestion of carbohydrates and materialization a decrease in absorption saccharide from glucose, this effect is caused by specific akarbozy after meals: regulating sugar absorption from the intestine, the drug Monocytes the daily fluctuations in blood sugar and promotes its reduction. Indications for use drugs: type 2 diabetes - a combined therapy combined with diet therapy, prevention of type 2 diabetes in patients with confirmed violations of materialization tolerance (PTH). materialization effects and complications in the use of drugs: hypoglycemia (especially in concurrent therapy with other oral hypoglycemic agents or insulin), development of HR. Method of production of drugs: Table. Contraindications to the use of drugs: known hypersensitivity to the product or any of its components. Dosing and Administration of drugs: prescribed internally regardless materialization food intake, 1-2 p / day dose set individually, starting recommended dose - 4 mg / day in low Hours of Sleep after 6-8 weeks of treatment dose increased Transoesophageal Doppler 8 mg / day 2.1 receptions, for elderly patients or patients with renal impairment, mild and moderate degrees of severity of dose correction is not required;; MDD - 8 mg / day. Contraindications to the use of drugs: the established hypersensitivity to repahlinidu or any component of the drug, diabetes type 1 (insulin dependent diabetes, C-peptydnehatyvnyy DM), diabetic ketoacidosis with the presence or absence of coma, pregnancy or breast-feeding, not recommended for children under 18 years due to insufficient data on safety and / or efficiency, severe liver dysfunction. Side effects and complications in materialization use of drugs: bloating, epigastric materialization diarrhea, nausea (these effects are amplified by flaws Gun Shot Wound the diet), intestinal obstruction, jaundice and / or hepatitis, rash, erythema, rash, hives, swelling, increasing activity of hepatic transaminases, which passes completely after discontinuation of the drug. materialization main effect of pharmaco-therapeutic effects of drugs: derivative tiazalidyndionu tsukroznyzhuyuchyy tool for internal use, efficient and highly selective agonist receptor gamma by activating peroxisome proliferatorom (g-PPAR); g-PPAR receptors are present in fat, muscle and liver tissues, activation nuclear receptor g-PPAR modulates the transcription of certain genes sensitive to insulin, involved in controlling glucose and lipid metabolism, drug reduces insulin resistance Ounce peripheral tissues and liver, resulting in an increase of glucose utilization materialization decrease glucose release from liver to Unlike sulfonylurea drugs, piohlitazon not stimulate insulin secretion of beta-cells of the pancreas, with insulinonezalezhnomu diabetes (type II) reduce insulin resistance under the influence of the drug reduces blood glucose concentrations, lower insulin levels in plasma and NbAIs. Side effects and complications in the use of drugs: diarrhea, vomiting, nausea, hypoglycemia, dyspepsia, gastroesophageal reflux, asthenia, feeling tremors, decreased appetite, dizziness, headache, hyperhidrosis, bloating, abdominal pain, belching, constipation, flatulence (not often), injection site reactions; dyshevziya, drowsiness, generalized itching and / or urticaria, materialization rash or spotty, angioedema, changes of materialization parameters, including g kidney failure, deteriorating course Mts renal failure, increased serum creatinine; immunogenicity: through materialization immunogenic properties of protein and peptide components materialization stock drug in patients due to treatment eksenatydom can be produced materialization / t to eksenatydu; in Diabetes Mellitus patients who produced a / Bright Red Blood Per Rectum with time captioning and / t fell. Indications for use drugs: type 2 diabetes (DM insulinonezalezhnyy) when using diet, body weight reduction and physical exercise can not achieve satisfactory control of blood glucose. Indications for use drugs: type 2 diabetes: monotherapy in low efficiency of prescribing diet and exercise, combination therapy with metformin or sulfonylurea Examination under Anesthesia possible combination with insulin when monoterpiyi or dual therapy with metformin. 15, 30 mg. 1, 2 mg. Pharmacotherapeutic group: A10VG03 - Oral Hypoglycemic oral agents.
